Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 297

1.

MOG encephalomyelitis: distinct clinical, MRI and CSF features in patients with longitudinal extensive transverse myelitis as first clinical presentation.

Loos J, Pfeuffer S, Pape K, Ruck T, Luessi F, Spreer A, Zipp F, Meuth SG, Bittner S.

J Neurol. 2020 Feb 13. doi: 10.1007/s00415-020-09755-x. [Epub ahead of print]

PMID:
32055995
2.

Covarying patterns of white matter lesions and cortical atrophy predict progression in early MS.

Muthuraman M, Fleischer V, Kroth J, Ciolac D, Radetz A, Koirala N, Gonzalez-Escamilla G, Wiendl H, Meuth SG, Zipp F, Groppa S.

Neurol Neuroimmunol Neuroinflamm. 2020 Feb 5;7(3). pii: e681. doi: 10.1212/NXI.0000000000000681. Print 2020 May 4.

3.

Association of intrathecal pleocytosis and IgG synthesis with axonal damage in early MS.

Engel S, Steffen F, Uphaus T, Scholz-Kreisel P, Zipp F, Bittner S, Luessi F.

Neurol Neuroimmunol Neuroinflamm. 2020 Feb 4;7(3). pii: e679. doi: 10.1212/NXI.0000000000000679. Print 2020 May 4.

4.

Continuous reorganization of cortical information flow in multiple sclerosis: A longitudinal fMRI effective connectivity study.

Fleischer V, Muthuraman M, Anwar AR, Gonzalez-Escamilla G, Radetz A, Gracien RM, Bittner S, Luessi F, Meuth SG, Zipp F, Groppa S.

Sci Rep. 2020 Jan 21;10(1):806. doi: 10.1038/s41598-020-57895-x.

5.

The Rare IL22RA2 Signal Peptide Coding Variant rs28385692 Decreases Secretion of IL-22BP Isoform-1, -2 and -3 and Is Associated with Risk for Multiple Sclerosis.

Gómez-Fernández P, Lopez de Lapuente Portilla A, Astobiza I, Mena J, Urtasun A, Altmann V, Matesanz F, Otaegui D, Urcelay E, Antigüedad A, Malhotra S, Montalban X, Castillo-Triviño T, Espino-Paisán L, Aktas O, Buttmann M, Chan A, Fontaine B, Gourraud PA, Hecker M, Hoffjan S, Kubisch C, Kümpfel T, Luessi F, Zettl UK, Zipp F, Alloza I, Comabella M, Lill CM, Vandenbroeck K.

Cells. 2020 Jan 10;9(1). pii: E175. doi: 10.3390/cells9010175.

6.

PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disorders.

Engel S, Luessi F, Mueller A, Schopf RE, Zipp F, Bittner S.

Ther Adv Neurol Disord. 2020 Jan 2;13:1756286419895155. doi: 10.1177/1756286419895155. eCollection 2020.

7.

IL-17+ CD8+ T cell suppression by dimethyl fumarate associates with clinical response in multiple sclerosis.

Lückel C, Picard F, Raifer H, Campos Carrascosa L, Guralnik A, Zhang Y, Klein M, Bittner S, Steffen F, Moos S, Marini F, Gloury R, Kurschus FC, Chao YY, Bertrams W, Sexl V, Schmeck B, Bonetti L, Grusdat M, Lohoff M, Zielinski CE, Zipp F, Kallies A, Brenner D, Berger M, Bopp T, Tackenberg B, Huber M.

Nat Commun. 2019 Dec 16;10(1):5722. doi: 10.1038/s41467-019-13731-z.

8.

β1-Integrin- and KV1.3 channel-dependent signaling stimulates glutamate release from Th17 cells.

Birkner K, Wasser B, Ruck T, Thalman C, Luchtman D, Pape K, Schmaul S, Bitar L, Krämer-Albers EM, Stroh A, Meuth SG, Zipp F, Bittner S.

J Clin Invest. 2020 Feb 3;130(2):715-732. doi: 10.1172/JCI126381.

9.

NfL (Neurofilament Light Chain) Levels as a Predictive Marker for Long-Term Outcome After Ischemic Stroke.

Uphaus T, Bittner S, Gröschel S, Steffen F, Muthuraman M, Wasser K, Weber-Krüger M, Zipp F, Wachter R, Gröschel K.

Stroke. 2019 Nov;50(11):3077-3084. doi: 10.1161/STROKEAHA.119.026410. Epub 2019 Sep 20.

PMID:
31537188
10.

Intrathecal B-cell accumulation and axonal damage distinguish MRI-based benign from aggressive onset in MS.

Engel S, Friedrich M, Muthuraman M, Steffen F, Poplawski A, Groppa S, Bittner S, Zipp F, Luessi F.

Neurol Neuroimmunol Neuroinflamm. 2019 Jul 19;6(5). pii: e595. doi: 10.1212/NXI.0000000000000595. Print 2019 Sep.

11.

Imaging in mice and men: Pathophysiological insights into multiple sclerosis from conventional and advanced MRI techniques.

Krämer J, Brück W, Zipp F, Cerina M, Groppa S, Meuth SG.

Prog Neurobiol. 2019 Nov;182:101663. doi: 10.1016/j.pneurobio.2019.101663. Epub 2019 Jul 30. Review.

PMID:
31374243
12.

[Diagnostics and treatment of tuberculosis under immunotherapy for multiple sclerosis : Current status and recommendations in Germany].

Bittner S, Engel S, Lange C, Weber MS, Haghikia A, Luessi F, Korn T, Klotz L, Bayas A, Paul F, Heesen C, Stangel M, Wildemann B, Bergh FT, Tackenberg B, Trebst C, Warnke C, Linker R, Kerschensteiner M, Zettl U, Tumani H, Brück W, Meuth SG, Kümpfel T, Hemmer B, Wiendl H, Gold R, Zipp F.

Nervenarzt. 2019 Dec;90(12):1245-1253. doi: 10.1007/s00115-019-0760-0. Review. German.

PMID:
31297574
13.

Implementing the 2017 McDonald criteria for the diagnosis of multiple sclerosis.

Zipp F, Oh J, Fragoso YD, Waubant E.

Nat Rev Neurol. 2019 Aug;15(8):441-445. doi: 10.1038/s41582-019-0194-0.

PMID:
31086264
14.

Automated segmentation of changes in FLAIR-hyperintense white matter lesions in multiple sclerosis on serial magnetic resonance imaging.

Schmidt P, Pongratz V, Küster P, Meier D, Wuerfel J, Lukas C, Bellenberg B, Zipp F, Groppa S, Sämann PG, Weber F, Gaser C, Franke T, Bussas M, Kirschke J, Zimmer C, Hemmer B, Mühlau M.

Neuroimage Clin. 2019;23:101849. doi: 10.1016/j.nicl.2019.101849. Epub 2019 May 2.

15.

Longitudinal cortical network reorganization in early relapsing-remitting multiple sclerosis.

Fleischer V, Koirala N, Droby A, Gracien RM, Deichmann R, Ziemann U, Meuth SG, Muthuraman M, Zipp F, Groppa S.

Ther Adv Neurol Disord. 2019 Apr 24;12:1756286419838673. doi: 10.1177/1756286419838673. eCollection 2019.

16.

Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis.

Gasperi C, Salmen A, Antony G, Bayas A, Heesen C, Kümpfel T, Linker RA, Paul F, Stangel M, Tackenberg B, Bergh FT, Warnke C, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Tumani H, Gold R, Hemmer B; German Competence Network of Multiple Sclerosis.

JAMA Neurol. 2019 Jul 1;76(7):841-849. doi: 10.1001/jamaneurol.2019.0905.

PMID:
31034002
17.

Immunoneuropsychiatry - novel perspectives on brain disorders.

Pape K, Tamouza R, Leboyer M, Zipp F.

Nat Rev Neurol. 2019 Jun;15(6):317-328. doi: 10.1038/s41582-019-0174-4. Review.

PMID:
30988501
18.

Neuronal ICAM-5 Plays a Neuroprotective Role in Progressive Neurodegeneration.

Birkner K, Loos J, Gollan R, Steffen F, Wasser B, Ruck T, Meuth SG, Zipp F, Bittner S.

Front Neurol. 2019 Mar 12;10:205. doi: 10.3389/fneur.2019.00205. eCollection 2019.

19.

Vemurafenib and cobimetinib combination therapy for BRAFV600E-mutated melanoma favors posterior reversible encephalopathy syndrome.

Engel S, Luessi F, Henning B, Bittner S, Loquai C, Zipp F.

Ann Oncol. 2019 Jun 1;30(6):1014-1016. doi: 10.1093/annonc/mdz114. No abstract available.

PMID:
30911762
20.

Correction: Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis.

Li R, Rezk A, Ghadiri M, Luessi F, Zipp F, Li H, Giacomini PS, Antel J, Bar-Or A.

J Immunol. 2019 Apr 1;202(7):2172. doi: 10.4049/jimmunol.1900114. Epub 2019 Feb 15. No abstract available.

PMID:
30770414
21.

[Milestone or missed opportunity? : Commentary on the revision of the McDonald criteria 2017].

Pape K, Zipp F.

Nervenarzt. 2019 Feb;90(2):183-184. doi: 10.1007/s00115-019-0682-x. German. No abstract available.

PMID:
30729270
22.

Evidence for a white matter lesion size threshold to support the diagnosis of relapsing remitting multiple sclerosis.

Grahl S, Pongratz V, Schmidt P, Engl C, Bussas M, Radetz A, Gonzalez-Escamilla G, Groppa S, Zipp F, Lukas C, Kirschke J, Zimmer C, Hoshi M, Berthele A, Hemmer B, Mühlau M.

Mult Scler Relat Disord. 2019 Apr;29:124-129. doi: 10.1016/j.msard.2019.01.042. Epub 2019 Jan 28.

PMID:
30711877
23.

Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS).

Johnen A, Bürkner PC, Landmeyer NC, Ambrosius B, Calabrese P, Motte J, Hessler N, Antony G, König IR, Klotz L, Hoshi MM, Aly L, Groppa S, Luessi F, Paul F, Tackenberg B, Bergh FT, Kümpfel T, Tumani H, Stangel M, Weber F, Bayas A, Wildemann B, Heesen C, Zettl UK, Zipp F, Hemmer B, Meuth SG, Gold R, Wiendl H, Salmen A; German Competence Network Multiple Sclerosis (KKNMS).

J Neurol. 2019 Feb;266(2):386-397. doi: 10.1007/s00415-018-9142-y. Epub 2018 Dec 4.

24.

Targeting Voltage-Dependent Calcium Channels with Pregabalin Exerts a Direct Neuroprotective Effect in an Animal Model of Multiple Sclerosis.

Hundehege P, Fernandez-Orth J, Römer P, Ruck T, Müntefering T, Eichler S, Cerina M, Epping L, Albrecht S, Menke AF, Birkner K, Göbel K, Budde T, Zipp F, Wiendl H, Gorji A, Bittner S, Meuth SG.

Neurosignals. 2018;26(1):77-93. doi: 10.1159/000495425. Epub 2018 Nov 27. Review.

25.

Publisher Correction: Maladaptive cortical hyperactivity upon recovery from experimental autoimmune encephalomyelitis.

Ellwardt E, Pramanik G, Luchtman D, Novkovic T, Jubal ER, Vogt J, Arnoux I, Vogelaar CF, Mandal S, Schmalz M, Barger Z, Ruiz de Azua I, Kuhlmann T, Lutz B, Mittmann T, Bittner S, Zipp F, Stroh A.

Nat Neurosci. 2019 Jan;22(1):144. doi: 10.1038/s41593-018-0274-2.

PMID:
30405214
26.

EGFL7 - a potential therapeutic target for multiple sclerosis?

Uphaus T, Zipp F, Larochelle C.

Expert Opin Ther Targets. 2018 Nov;22(11):899-902. doi: 10.1080/14728222.2018.1535595. Epub 2018 Oct 17. No abstract available.

PMID:
30312112
27.

Maladaptive cortical hyperactivity upon recovery from experimental autoimmune encephalomyelitis.

Ellwardt E, Pramanik G, Luchtman D, Novkovic T, Jubal ER, Vogt J, Arnoux I, Vogelaar CF, Mandal S, Schmalz M, Barger Z, Ruiz de Azua I, Kuhlmann T, Lutz B, Mittmann T, Bittner S, Zipp F, Stroh A.

Nat Neurosci. 2018 Oct;21(10):1392-1403. doi: 10.1038/s41593-018-0193-2. Epub 2018 Sep 26. Erratum in: Nat Neurosci. 2019 Jan;22(1):144.

PMID:
30258239
28.

Discriminative power of intra-retinal layers in early multiple sclerosis using 3D OCT imaging.

Seitz CB, Droby A, Zaubitzer L, Krämer J, Paradis M, Klotz L, Wiendl H, Groppa S, Meuth SG, Zipp F, Fleischer V.

J Neurol. 2018 Oct;265(10):2284-2294. doi: 10.1007/s00415-018-8988-3. Epub 2018 Aug 2.

PMID:
30073502
29.

Targeting prohibitins at the cell surface prevents Th17-mediated autoimmunity.

Buehler U, Schulenburg K, Yurugi H, Šolman M, Abankwa D, Ulges A, Tenzer S, Bopp T, Thiede B, Zipp F, Rajalingam K.

EMBO J. 2018 Aug 15;37(16). pii: e99429. doi: 10.15252/embj.201899429. Epub 2018 Jul 26.

30.

GFAPα IgG-associated encephalitis upon daclizumab treatment of MS.

Luessi F, Engel S, Spreer A, Bittner S, Zipp F.

Neurol Neuroimmunol Neuroinflamm. 2018 Jul 13;5(5):e481. doi: 10.1212/NXI.0000000000000481. eCollection 2018 Sep.

31.

DNA methylation as a mediator of HLA-DRB1*15:01 and a protective variant in multiple sclerosis.

Kular L, Liu Y, Ruhrmann S, Zheleznyakova G, Marabita F, Gomez-Cabrero D, James T, Ewing E, Lindén M, Górnikiewicz B, Aeinehband S, Stridh P, Link J, Andlauer TFM, Gasperi C, Wiendl H, Zipp F, Gold R, Tackenberg B, Weber F, Hemmer B, Strauch K, Heilmann-Heimbach S, Rawal R, Schminke U, Schmidt CO, Kacprowski T, Franke A, Laudes M, Dilthey AT, Celius EG, Søndergaard HB, Tegnér J, Harbo HF, Oturai AB, Olafsson S, Eggertsson HP, Halldorsson BV, Hjaltason H, Olafsson E, Jonsdottir I, Stefansson K, Olsson T, Piehl F, Ekström TJ, Kockum I, Feinberg AP, Jagodic M.

Nat Commun. 2018 Jun 19;9(1):2397. doi: 10.1038/s41467-018-04732-5.

32.

AAN unveils new guidelines for MS disease-modifying therapy.

Bittner S, Zipp F.

Nat Rev Neurol. 2018 Jul;14(7):384-386. doi: 10.1038/s41582-018-0026-7. No abstract available.

PMID:
29895963
33.

[New aspects of immunotherapy in multiple sclerosis].

Pape K, Zipp F, Bittner S.

Nervenarzt. 2018 Dec;89(12):1365-1370. doi: 10.1007/s00115-018-0542-0. Review. German.

PMID:
29881971
34.

Monitoring B-cell repopulation after depletion therapy in neurologic patients.

Ellwardt E, Ellwardt L, Bittner S, Zipp F.

Neurol Neuroimmunol Neuroinflamm. 2018 Apr 25;5(4):e463. doi: 10.1212/NXI.0000000000000463. eCollection 2018 Jul.

35.

Characterizing Microstructural Tissue Properties in Multiple Sclerosis with Diffusion MRI at 7 T and 3 T: The Impact of the Experimental Design.

De Santis S, Bastiani M, Droby A, Kolber P, Zipp F, Pracht E, Stoecker T, Groppa S, Roebroeck A.

Neuroscience. 2019 Apr 1;403:17-26. doi: 10.1016/j.neuroscience.2018.03.048. Epub 2018 Apr 7.

36.

CCR7 on CD4+ T Cells Plays a Crucial Role in the Induction of Experimental Autoimmune Encephalomyelitis.

Belikan P, Bühler U, Wolf C, Pramanik GK, Gollan R, Zipp F, Siffrin V.

J Immunol. 2018 Apr 15;200(8):2554-2562. doi: 10.4049/jimmunol.1701419. Epub 2018 Mar 16.

37.

Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.

Siller N, Kuhle J, Muthuraman M, Barro C, Uphaus T, Groppa S, Kappos L, Zipp F, Bittner S.

Mult Scler. 2019 Apr;25(5):678-686. doi: 10.1177/1352458518765666. Epub 2018 Mar 15.

PMID:
29542376
38.

Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis.

Graetz C, Gröger A, Luessi F, Salmen A, Zöller D, Schultz J, Siller N, Fleischer V, Bellenberg B, Berthele A, Biberacher V, Havla J, Hecker M, Hohlfeld R, Infante-Duarte C, Kirschke JS, Kümpfel T, Linker R, Paul F, Pfeuffer S, Sämann P, Toenges G, Weber F, Zettl UK, Jahn-Eimermacher A, Antony G, Groppa S, Wiendl H, Hemmer B, Mühlau M, Lukas C, Gold R, Lill CM, Zipp F.

Mult Scler. 2019 Apr;25(5):661-668. doi: 10.1177/1352458518763541. Epub 2018 Mar 13.

PMID:
29532745
39.

Treatment choices and neuropsychological symptoms of a large cohort of early MS.

von Bismarck O, Dankowski T, Ambrosius B, Hessler N, Antony G, Ziegler A, Hoshi MM, Aly L, Luessi F, Groppa S, Klotz L, Meuth SG, Tackenberg B, Stoppe M, Then Bergh F, Tumani H, Kümpfel T, Stangel M, Heesen C, Wildemann B, Paul F, Bayas A, Warnke C, Weber F, Linker RA, Ziemann U, Zettl UK, Zipp F, Wiendl H, Hemmer B, Gold R, Salmen A.

Neurol Neuroimmunol Neuroinflamm. 2018 Mar 1;5(3):e446. doi: 10.1212/NXI.0000000000000446. eCollection 2018 May.

40.

Studying the blood-brain barrier will provide new insights into neurodegeneration - Commentary.

Bittner S, Zipp F.

Mult Scler. 2018 Jul;24(8):1026-1028. doi: 10.1177/1352458518759430. Epub 2018 Mar 5. No abstract available.

PMID:
29504451
41.

Fast direct neuronal signaling via the IL-4 receptor as therapeutic target in neuroinflammation.

Vogelaar CF, Mandal S, Lerch S, Birkner K, Birkenstock J, Bühler U, Schnatz A, Raine CS, Bittner S, Vogt J, Kipnis J, Nitsch R, Zipp F.

Sci Transl Med. 2018 Feb 28;10(430). pii: eaao2304. doi: 10.1126/scitranslmed.aao2304.

PMID:
29491183
42.

EGFL7 reduces CNS inflammation in mouse.

Larochelle C, Uphaus T, Broux B, Gowing E, Paterka M, Michel L, Dudvarski Stankovic N, Bicker F, Lemaître F, Prat A, Schmidt MHH, Zipp F.

Nat Commun. 2018 Feb 26;9(1):819. doi: 10.1038/s41467-018-03186-z.

43.

Preservation of neuronal function as measured by clinical and MRI endpoints in relapsing-remitting multiple sclerosis: how effective are current treatment strategies?

Graetz C, Groppa S, Zipp F, Siller N.

Expert Rev Neurother. 2018 Mar;18(3):203-219. doi: 10.1080/14737175.2018.1438190. Epub 2018 Feb 15. Review.

PMID:
29411688
44.

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.

Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F.

Mult Scler. 2018 Feb;24(2):96-120. doi: 10.1177/1352458517751049. Epub 2018 Jan 20. Erratum in: Mult Scler. 2020 Feb 4;:1352458520906383.

PMID:
29353550
45.

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis.

Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F.

Eur J Neurol. 2018 Feb;25(2):215-237. doi: 10.1111/ene.13536. Epub 2018 Jan 19. Erratum in: Eur J Neurol. 2018 Mar;25(3):605.

PMID:
29352526
46.

Increased cerebrospinal fluid albumin and immunoglobulin A fractions forecast cortical atrophy and longitudinal functional deterioration in relapsing-remitting multiple sclerosis.

Kroth J, Ciolac D, Fleischer V, Koirala N, Krämer J, Muthuraman M, Luessi F, Bittner S, Gonzalez-Escamilla G, Zipp F, Meuth SG, Groppa S.

Mult Scler. 2019 Mar;25(3):338-343. doi: 10.1177/1352458517748474. Epub 2017 Dec 11.

PMID:
29226779
47.

Graph Theoretical Framework of Brain Networks in Multiple Sclerosis: A Review of Concepts.

Fleischer V, Radetz A, Ciolac D, Muthuraman M, Gonzalez-Escamilla G, Zipp F, Groppa S.

Neuroscience. 2019 Apr 1;403:35-53. doi: 10.1016/j.neuroscience.2017.10.033. Epub 2017 Nov 1. Review.

PMID:
29101079
48.

Disease reactivation after switching from natalizumab to daclizumab.

Uphaus T, Oberwittler C, Groppa S, Zipp F, Bittner S.

J Neurol. 2017 Dec;264(12):2491-2494. doi: 10.1007/s00415-017-8622-9. Epub 2017 Oct 3.

PMID:
28975400
49.

The Role of ERK Signaling in Experimental Autoimmune Encephalomyelitis.

Birkner K, Wasser B, Loos J, Plotnikov A, Seger R, Zipp F, Witsch E, Bittner S.

Int J Mol Sci. 2017 Sep 15;18(9). pii: E1990. doi: 10.3390/ijms18091990.

50.

Single-cell profiling reveals GPCR heterogeneity and functional patterning during neuroinflammation.

Tischner D, Grimm M, Kaur H, Staudenraus D, Carvalho J, Looso M, Günther S, Wanke F, Moos S, Siller N, Breuer J, Schwab N, Zipp F, Waisman A, Kurschus FC, Offermanns S, Wettschureck N.

JCI Insight. 2017 Aug 3;2(15). pii: 95063. doi: 10.1172/jci.insight.95063. eCollection 2017 Aug 3.

Supplemental Content

Support Center